Boekhorst Paul Francis Olivier Te - 12 Nov 2026 Form 4 Insider Report for IMMUCELL CORP /DE/ (ICCC)

SEC form
4
Accepted by SEC
16 Nov 2026, 13:54:04 UTC
Prior SEC filing
22 Jun 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Boekhorst Paul Francis Olivier Te filed Form 4 for IMMUCELL CORP /DE/ (ICCC) on 16 Nov 2026.

Key facts

  • This page summarizes Boekhorst Paul Francis Olivier Te's Form 4 filing for IMMUCELL CORP /DE/ (ICCC).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 16 Nov 2026, 13:54.

Change

  • Previous filing in this sequence was filed on 22 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002095704 Primary reporting owner

te Boekhorst Paul Francis Olivier

Relationship
President and CEO, Director

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ICCC transaction

Common Stock, par value $.10 per share

Options Exercise

Transaction value
Shares
+16,393
Change %
+92%
Price
$6.10*
Shares after
34,131
Date
12 Nov 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ICCC transaction Derivative

Incentive Stock Options (Right to buy)

Options Exercise

Transaction value
Shares
-16,393
Change %
-22%
Price
$0.000000*
Shares after
57,884
Date
12 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
16,393
Exercise price
$6.10
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Total beneficial ownership shown here reflects a correction in the amount previously reported June 22, 2026 on Form 4 (which correctly reported the number of shares purchases but overstated total ownership by 47 shares).

Footnote F2

The stock option vests in three annual installments of 24.759 shares on the first, second and third anniversaries of the November 7, 2026 grant date. The first installment vested on November7, 2026.

Footnote F3

Represents the number of shares remaining subject to the option following the reported exercise.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .